• Publications
  • Influence
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six‐month results of a prospective randomized clinical trial
To compare standard‐of‐care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branchExpand
  • 38
  • 4
Risk factors for complications after congenital cataract surgery without intraocular lens implantation in the first 18 months of life.
PURPOSE To determine individual risk factors for the development of postoperative complications after pediatric cataract surgery in the first 18 months of life. DESIGN Interventional, consecutiveExpand
  • 72
  • 3
Incidence of posterior vitreous detachment after cataract surgery
PURPOSE: To report the incidence of posterior vitreous detachment (PVD) after uneventful state‐of‐the‐art small‐incision phacoemulsification with implantation of a posterior chamber intraocular lensExpand
  • 59
  • 3
  • PDF
Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)
To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg according to their European labels in macular oedema secondary to branch retinal vein occlusion (BRVO) in aExpand
  • 27
  • 3
Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis®)
Purpose This prospective study examines the changes in short-term intraocular pressure (IOP) in patients with wet age-related macular degeneration (AMD) receiving intravitreal injections of 0.05 mLExpand
  • 55
  • 2
High prevalence of resistance to APC in young patients with retinal vein occlusion
Abstract. Resistance to activated protein C (APC) is among the coagulation disorders that have been implicated in retinal vein occlusion. However, since retinal vascular occlusions may be due to aExpand
  • 48
  • 2
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.
PURPOSE To compare the efficacy and safety of the European labels of ranibizumab 0.5 mg vs dexamethasone 0.7 mg in patients with macular edema secondary to central retinal vein occlusion (CRVO). Expand
  • 21
  • 2
Experimental percutaneous cannulation of the supraorbital arteries: implication for future therapy.
PURPOSE There is some evidence to suggest that thrombolysis has a beneficial effect in retinal vessel occlusion. However, there is concern that this therapeutic approach carries the risk ofExpand
  • 18
  • 2
  • PDF
Intravitreale Gabe von rt-PA und Gas zur Behandlung kleinflächiger subfovealer Blutungen bei altersbezogener Makuladegeneration
Background: Subfoveal haemorrhage is a serious complication of choroidal neovascularization in age-related macular degeneration (ARMD). Recent studies have demonstrated that intravitreal injectionsExpand
  • 13
  • 1
Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy.
PURPOSE To evaluate the incidence of and risk factors for subretinal hemorrhages in age-related macular degeneration (AMD) patients on anticoagulation or antiplatelet therapy. DESIGN Retrospective,Expand
  • 39
  • 1